[go: up one dir, main page]

WO1996013267A3 - Combinations of prostaglandins and brimonidine or derivatives thereof for the treatment of glaucoma - Google Patents

Combinations of prostaglandins and brimonidine or derivatives thereof for the treatment of glaucoma Download PDF

Info

Publication number
WO1996013267A3
WO1996013267A3 PCT/US1995/013624 US9513624W WO9613267A3 WO 1996013267 A3 WO1996013267 A3 WO 1996013267A3 US 9513624 W US9513624 W US 9513624W WO 9613267 A3 WO9613267 A3 WO 9613267A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
brimonidine
glaucoma
derivatives
prostaglandins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1995/013624
Other languages
French (fr)
Other versions
WO1996013267A2 (en
Inventor
Michael E Garst
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of WO1996013267A2 publication Critical patent/WO1996013267A2/en
Publication of WO1996013267A3 publication Critical patent/WO1996013267A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention concerns combinations of alpha adrenergic agents such as brimonidine and its derivatives as represented by formula (I) wherein each Y is independently selected from the group consisting of N, N-CH3, O, S and C-R1; R1 is hydrogen, lower alkyl or oxo; R2, R3 and R4 are independently selected from the group consisting of hydrogen, halogen, lower alkyl and lower alkenyl; n is an integer from 1 to 3; and a broken line beside a solid line indicates either a single or a double bond with the proviso that when n=1, both bonds from Y to C-R1 cannot be double bonds, and prostaglandins known in the art to cause lowering of intraocular pressure which are useful in compositions, methods of treatment and articles of manufacture for the treatment of glaucoma and alleviation of elevated intraocular pressure.
PCT/US1995/013624 1994-10-27 1995-10-20 Combinations of prostaglandins and brimonidine or derivatives thereof for the treatment of glaucoma Ceased WO1996013267A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33005094A 1994-10-27 1994-10-27
US08/330,050 1994-10-27

Publications (2)

Publication Number Publication Date
WO1996013267A2 WO1996013267A2 (en) 1996-05-09
WO1996013267A3 true WO1996013267A3 (en) 1996-07-04

Family

ID=23288106

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/013624 Ceased WO1996013267A2 (en) 1994-10-27 1995-10-20 Combinations of prostaglandins and brimonidine or derivatives thereof for the treatment of glaucoma

Country Status (1)

Country Link
WO (1) WO1996013267A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856329A (en) * 1995-06-28 1999-01-05 Allergan Method of using (2-imidazolin-2-ylamino) quinoxalines in treating ocular neural injury
US6194415B1 (en) 1995-06-28 2001-02-27 Allergan Sales, Inc. Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury
US6353014B1 (en) 1996-11-12 2002-03-05 Alcon Laboratories, Inc. 15-ketal postaglandins for the treatment of glaucoma or ocular hypertension
EP0968183A2 (en) 1997-03-07 2000-01-05 Alcon Laboratories, Inc. 13-thia prostaglandins for use in glaucoma therapy
US6242442B1 (en) * 1998-12-17 2001-06-05 Alcon Laboratories, Inc. Brinzolamide and brimonidine for treating ocular conditions
US7439241B2 (en) 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US8410102B2 (en) 2003-05-27 2013-04-02 Galderma Laboratories Inc. Methods and compositions for treating or preventing erythema
EP2329849B1 (en) 2009-11-18 2015-04-29 Galderma Research & Development Combination of alpha-2 adrenergic receptor agonist and non-steroidal anti-inflammatory agent for treating or preventing an inflammatory skin disorder
US8394800B2 (en) 2009-11-19 2013-03-12 Galderma Laboratories, L.P. Method for treating psoriasis
HUE033143T2 (en) 2010-03-26 2017-11-28 Galderma Res & Dev Compositions comprising brimonidine for the treatment of erythema
KR20150058551A (en) 2010-03-26 2015-05-28 갈데르마 리써어치 앤드 디벨로프먼트 Improved methods and compositions for safe and effective treatment of telangiectasia
US8053427B1 (en) 2010-10-21 2011-11-08 Galderma R&D SNC Brimonidine gel composition
EP2444068B2 (en) 2010-10-21 2017-12-06 Galderma S.A. Brimonidine gel composition
JP2014520895A (en) * 2011-07-20 2014-08-25 アラーガン インコーポレイテッド Combination of fixed doses of bimatoprost and brimonidine

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994008585A1 (en) * 1992-10-13 1994-04-28 Alcon Laboratories, Inc. Combinations of prostaglandins and clonidine derivatives for the treatment of glaucoma

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994008585A1 (en) * 1992-10-13 1994-04-28 Alcon Laboratories, Inc. Combinations of prostaglandins and clonidine derivatives for the treatment of glaucoma

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SERLE JB: "Pharmacological advances in the treatment of glaucoma.", DRUGS AGING, SEP 1994, 5 (3) P156-70, NEW ZEALAND *

Also Published As

Publication number Publication date
WO1996013267A2 (en) 1996-05-09

Similar Documents

Publication Publication Date Title
WO1996013267A3 (en) Combinations of prostaglandins and brimonidine or derivatives thereof for the treatment of glaucoma
EP1225168A3 (en) Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
TR200003844T2 (en) Epothilone derivatives, their synthesis and uses
MY121967A (en) New 4-(oxyalkoxyphenyl)-3-oxy-piperidines for treating heart and kidney insufficiency
GEP20115347B (en) Heterocyclocarboxamide derivatives
IL157773A0 (en) 2-amino-propanol derivatives
BG103485A (en) Ketobanzamides as calpain inhibitors
MXPA03004165A (en) Rubber compounds that contain gels and inorganic peroxides.
AU3192195A (en) Thiazolidinedione derivatives, their production and use
WO1996013259A3 (en) Method and compositions for inhibiting protein kinases
CA2221110A1 (en) Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents for the treatment of ocular hypertension
EP0437030A3 (en) Use of 4-substituted imidazoles for lowering intraocular pressure
HK1049479A1 (en) Ocular hypotensive lipids
NZ506497A (en) Indole derivatives, pharmaceuticals thereof and their use in lowering intraocular pressure or for the treatment or prevention of glaucoma or ocular hypertension
ATE160792T1 (en) OLIGOMERIC, STERICALLY HINDERED POLYAMINE CROSSLINKERS AND COATING COMPOSITION CONTAINING THESE CROSSLINKERS
MY132550A (en) Acylaminoalkenylene-amide derivatives as nk1 and nk2 antogonists
WO1999002532A3 (en) Partially hydrogenated polycyclic compounds
AU6597790A (en) Use of 6- or 7-hydroxyindole derivatives as couplers and dyeing compositions and methods using these
MY100512A (en) New 6-or 7-methlenandrosta-1, 4-diene-3, 17-dione derivatives and process for their preparation.
WO2004019874A3 (en) Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma
WO2004054572A3 (en) Novel benzopyran analogs and their use for the treatment of glaucoma
EP1121932A4 (en) Remedies for ocular diseases
MY111216A (en) 2-hydroxy-3-[1-(1h-imidazol-4-yl)alkyl]-benzenecarboximidamides
WO2001044327A3 (en) Method for producing a polymeric conversion product
EP0355689A3 (en) Pyrano [f] quinoline derivatives and pharmaceutical compositions containing the same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase